MedTrace Logo

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

NCT03009058 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2024-11-25

Study results available
· View outcomes & findings →

Summary

During this open label study patients will receive IMM-101 in conjunction with a recognised standard of care for metastatic or unresectable cancer for the patient's specific tumour type.

The primary objective of the study is to provide safety data for IMM-101 in combination with a number of selected standard of care regimens.

Conditions

Interventions

BIOLOGICAL

IMM-101

A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365

DRUG

Gemcitabine

Standard of Care chemotherapy

DRUG

Nab-paclitaxel

Standard of Care chemotherapy

DRUG

Capecitabine

Standard of Care chemotherapy

DRUG

Folinic Acid

Standard of Care chemotherapy

DRUG

Fluorouracil

Standard of Care chemotherapy

DRUG

Irinotecan

Standard of Care chemotherapy

DRUG

Oxaliplatin

Standard of Care chemotherapy

BIOLOGICAL

cetuximab

Standard of Care immunotherapy

BIOLOGICAL

Anti-PD1

Standard of Care immunotherapy

BIOLOGICAL

Ipilimumab

Standard of Care immunotherapy

DRUG

Cyclophosphamide

Standard of Care chemotherapy

Sponsors & Collaborators

  • Immodulon Therapeutics Ltd

    lead INDUSTRY

Principal Investigators

  • David Cunningham, MD FRCP · Royal Marsden Hospital Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-31
Primary Completion
2017-08-30
Completion
2017-08-30

Countries

  • France
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03009058 on ClinicalTrials.gov